Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

U.S. FDA Approves Bayer’s Gadavistâ„¢ (Gadobutrol) Injection for MRI of the Central Nervous System

March 14, 2011 By Bio-Medicine.Org

WAYNE, N.J., March 14, 2011 /PRNewswire/ — Bayer HealthCare
Pharmaceuticals Inc. announced today that the U.S. Food and Drug
Administration has approved Gadavist™ (gadobutrol) Injection,
a macrocyclic gadolinium-based contrast agent (GBCA), for
intravenous use in diagnostic magnetic resonance imaging (MRI) in
adults and children (2 years of age and older) to detect and
visualize areas with disrupted blood brain barrier (BBB) and/or
abnormal vascularity of the central nervous system (CNS).
 

Gadavist is formulated at a higher concentration (1 mmol/mL)
compared to certain other GBCAs.  Compared to 0.5 molar
gadolinium-based contrast agents, the higher concentration of
Gadavist results in half the volume of administration and a more
compact contrast bolus.  It is important to closely examine
the dosing table in the full prescribing information to determine
the volume of Gadavist to be administered.

“The approval of Gadavist enriches our strong portfolio of MRI
contrast media and provides a new option for U.S. healthcare
providers in contrast-enhanced imaging of the CNS,” said John
Rotondo, Vice President, Commercial Operations, Bayer HealthCare
Pharmaceuticals.  “Our MR contrast agents are some of the most
widely used today, and Bayer is proud to be a world leader in
diagnostic imaging.”IMPORTANT SAFETY INFORMATIONWARNING:
NEPHROGENIC SYSTEMIC FIBROSIS (NSF)Gadolinium-based contrast agents
(GBCAs) increase the risk for NSF among patients with impaired
elimination of the drugs. Avoid use of GBCAs in these patients
unless the diagnostic information is essential and not available
with non-contrasted MRI or other modalities. NSF may result in
fatal or debilitating fibrosis affecting the skin, muscle and
internal organs.

The risk for NSF appears highest among patients with: Chronic,
severe kidney disease (GFR < 30 mL/min/1.73m(squared)), or Acute
kidney i

‘/>”/>

SOURCE

Related Articles Read More >

A rat holding its face with its paws
Ultrasound research with rats shows potential for depression therapy
Tivic Health CEO Jennifer Ernst
Sinus pain is just the beginning for Tivic Health’s CEO
A series of before-and-after brain scans showing improvement in long COVID patients after hyperbaric oxygen therapy
Long COVID study finds potential in hyperbaric oxygen therapy
microrobot-purdue-university
This microrobot device could remove brain hemorrhages caused by stroke

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech